These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19037197)

  • 1. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study.
    Rau T; Wuttke H; Michels LM; Werner U; Bergmann K; Kreft M; Fromm MF; Eschenhagen T
    Clin Pharmacol Ther; 2009 Mar; 85(3):269-72. PubMed ID: 19037197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
    Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
    Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users.
    Bijl MJ; Visser LE; van Schaik RH; Kors JA; Witteman JC; Hofman A; Vulto AG; van Gelder T; Stricker BH
    Clin Pharmacol Ther; 2009 Jan; 85(1):45-50. PubMed ID: 18784654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
    Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
    Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.
    Kirchheiner J; Heesch C; Bauer S; Meisel C; Seringer A; Goldammer M; Tzvetkov M; Meineke I; Roots I; Brockmöller J
    Clin Pharmacol Ther; 2004 Oct; 76(4):302-12. PubMed ID: 15470329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.
    Wuttke H; Rau T; Heide R; Bergmann K; Böhm M; Weil J; Werner D; Eschenhagen T
    Clin Pharmacol Ther; 2002 Oct; 72(4):429-37. PubMed ID: 12386645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients.
    Ismail R; Teh LK
    J Clin Pharm Ther; 2006 Feb; 31(1):99-109. PubMed ID: 16476126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy.
    Batty JA; Hall AS; White HL; Wikstrand J; de Boer RA; van Veldhuisen DJ; van der Harst P; Waagstein F; Hjalmarson Å; Kjekshus J; Balmforth AJ;
    Clin Pharmacol Ther; 2014 Mar; 95(3):321-30. PubMed ID: 24193112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension.
    Lefebvre J; Poirier L; Poirier P; Turgeon J; Lacourciere Y
    Br J Clin Pharmacol; 2007 May; 63(5):575-82. PubMed ID: 17094780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of metoprolol pharmacokinetics and hemodynamics by diphenhydramine coadministration during exercise testing in healthy premenopausal women.
    Sharma A; Pibarot P; Pilote S; Dumesnil JG; Arsenault M; Bélanger PM; Meibohm B; Hamelin BA
    J Pharmacol Exp Ther; 2005 Jun; 313(3):1172-81. PubMed ID: 15718288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients.
    Halling J; Weihe P; Brosen K
    Ther Drug Monit; 2008 Jun; 30(3):271-5. PubMed ID: 18520597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2D6 genotype and its relationship with metoprolol dose, concentrations and effect in patients with systolic heart failure.
    Sharp CF; Gardiner SJ; Jensen BP; Roberts RL; Troughton RW; Lainchbury JG; Begg EJ
    Pharmacogenomics J; 2009 Jun; 9(3):175-84. PubMed ID: 19365402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction - a prospective observational study.
    Anstensrud AK; Molden E; Haug HJ; Qazi R; Muriq H; Fosshaug LE; Spigset O; Øie E
    Eur J Clin Pharmacol; 2020 May; 76(5):673-683. PubMed ID: 31940084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure.
    Terra SG; Pauly DF; Lee CR; Patterson JH; Adams KF; Schofield RS; Belgado BS; Hamilton KK; Aranda JM; Hill JA; Yarandi HN; Walker JR; Phillips MS; Gelfand CA; Johnson JA
    Clin Pharmacol Ther; 2005 Mar; 77(3):127-37. PubMed ID: 15735607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rationale and methods of the UNAMET study (dose- and CYP2D6-genotype-dependent adverse drug reactions of metoprolol)--a contribution to quality improvement in pharmacotherapy].
    Fux R; Meisner C; Schwab M; Lorenz G; Mörike K; Gleiter CH
    Z Arztl Fortbild Qualitatssich; 2004 Nov; 98(8):689-94. PubMed ID: 15646732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity.
    Hamelin BA; Bouayad A; Méthot J; Jobin J; Desgagnés P; Poirier P; Allaire J; Dumesnil J; Turgeon J
    Clin Pharmacol Ther; 2000 May; 67(5):466-77. PubMed ID: 10824625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.
    Damy T; Pousset F; Caplain H; Hulot JS; Lechat P
    Fundam Clin Pharmacol; 2004 Feb; 18(1):113-23. PubMed ID: 14748763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction.
    Goryachkina K; Burbello A; Boldueva S; Babak S; Bergman U; Bertilsson L
    Eur J Clin Pharmacol; 2008 Dec; 64(12):1163-73. PubMed ID: 18648788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toward optimal treatment in women: the effect of sex on metoprolol-diphenhydramine interaction.
    Sharma A; Pibarot P; Pilote S; Dumesnil JG; Arsenault M; Bélanger PM; Meibohm B; Hamelin BA
    J Clin Pharmacol; 2010 Feb; 50(2):214-25. PubMed ID: 19948945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol.
    Liu J; Liu ZQ; Tan ZR; Chen XP; Wang LS; Zhou G; Zhou HH
    Clin Pharmacol Ther; 2003 Oct; 74(4):372-9. PubMed ID: 14534524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.